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Abstract
Background: Biannual ultrasound (US)—with or without alpha-fetoprotein (AFP)—is recommended by current
guidelines for the surveillance of hepatocellular carcinoma (HCC). However, the inadequate sensitivity of US has
been a concern. Magnetic resonance imaging (MRI) is known to have high sensitivity in detecting hepatic
malignancies, even without contrast enhancement. The purpose of our study is to compare US with noncontrast
(unenhanced) MRI for HCC surveillance of high-risk patients.
Methods/design: MIRACLE-HCC (usefulness of noncontrast MagnetIc Resonance imAging versus nonContrast
ultrasonography for surveiLlancE of HepatoCellular Carcinoma) is a prospective, single-center, nonblinded, balanced-
randomized, parallel-group study. This study was approved by our institutional review board, and informed consent
will be obtained from all participating patients. All patients with compensated liver cirrhosis will undergo
noncontrast US or MRI, with serum AFP testing every 6 months. If a suspicious lesion is newly detected, or if the
serum AFP level is elevated in an increasing trend for two consecutive tests, dynamic contrast-enhanced imaging
will be performed to confirm the diagnosis. The primary endpoints are detection rates of very early or early stage
HCC, stage distribution at the initial diagnosis, and false positive referral rates, which will be compared using
Fisher’s exact or chi-square tests. The study will include 416 patients in a tertiary academic medical center in
South Korea.
Discussion: MIRACLE-HCC is the first prospective randomized trial to compare the effectiveness of noncontrast MRI
and noncontrast US in the surveillance of HCC in at-risk patients. The results of this trial will show whether
noncontrast MRI surveillance is superior to noncontrast US surveillance in the early detection of HCC. The trial will
also determine whether there are fewer false referrals with noncontrast MRI than with noncontrast US and,
eventually, whether there is improvement in the overall survival of HCC patients.
Trial registration: The date of trial registration (ClincalTrials.gov: NCT02514434) for this study is July 23, 2015.
Enrollment of participants was finished in November 2017. No authors have relationships, conditions, or
circumstances that present potential conflicts of interest.
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Background
Periodic surveillance of patients at high risk of developing
hepatocellular carcinoma (HCC) is known to improve
early tumor detection and overall survival [1–4]. Biannual
noncontrast ultrasound (US)—with or without alpha-feto-
protein (AFP)—is recommended as a surveillance imaging
modality by the current guidelines, mainly because of wide
accessibility and low cost [5–8]. However, the inadequate
sensitivity of US has been a concern [9], with a
meta-analysis reporting a pooled sensitivity of 63% for
detecting early stage HCC [10]. Moreover, the reported
sensitivities of US vary widely—from 32 to 92%—in
clinical practice [11, 12], demonstrating that US results
can be greatly affected by several factors, including
imaging protocols, equipment, patient characteristics, and
operator experience [13–15].
Given the limited effectiveness of noncontrast US,
other imaging modalities, such as contrast-enhanced US,
contrast-enhanced computed tomography (CT), and
contrast-enhanced magnetic resonance imaging (MRI),
have been suggested for use in HCC surveillance [16–21].
However, contrast-enhanced US still has the limitation of
being greatly influenced by patient characteristics (i.e.,
poor echogenic window or liver macro-nodularity) and
operator experience, and CT may not be a desirable
surveillance modality due to the potential risk of radiation
exposure [22]. Although contrast-enhanced MRI is super-
ior to noncontrast (unenhanced) US in detecting small tu-
mors in patients with chronic liver disease [23], its use in
HCC surveillance may be hampered by limited accessibil-
ity and high cost, as well as the issue of gadolinium-based
contrast agent accumulation in human organs [24].
Even without contrast enhancement, MRI is likely to
show higher sensitivity than US in detecting hepatic
malignancies [25]. Furthermore, noncontrast MRI does
not include dynamic sequences using contrast agents,
thereby reducing the cost and scanning time, and avoid-
ing the accumulation of gadolinium-based contrast
media. We believe that these advantages could make
noncontrast MRI a potential alternative to US for HCC
surveillance. Therefore, we set up a prospective random-
ized trial to compare noncontrast US with noncontrast
MRI in HCC surveillance of high-risk patients.
Methods/design
Study design and setting
The current trial (usefulness of noncontrast MagnetIc
Resonance imAging versus nonContrast ultrasonog-
raphy for surveiLlancE of HepatoCellular Carcinoma
[MIRACLE-HCC]) is a prospective, single-center, non-
blinded, balanced-randomized, parallel-group study.
This trial is registered with ClinicalTrials.gov (identi-
fier: NCT02514434), and the date of registration is
July 23, 2015.
This study has been approved by our institutional re-
view board (IRB) and will be conducted in accordance
with the ethical principles stated in the Declaration of
Helsinki and Good Clinical Practice guidelines. Any
modifications to the protocol will require a formal
amendment to the protocol and will be reviewed by the
IRB. These modifications will be implemented only after
they are approved by the IRB and notified to all partici-
pating investigators and patients. From August 2015, we
recruited patients who started or had been under sur-
veillance for HCC at the liver cancer center of Severance
Hospital, a 2260-bed academic tertiary referral hospital
in Seoul, South Korea. Before inclusion in the study,
informed written consent has been obtained from each
patient. The last patient was enrolled on November 29,
2017, and follow-up to see primary and secondary
endpoints is still ongoing.
In South Korea, whose total population is approxi-
mately 51 million, the crude incidence rate of liver
cancer in 2013 was 32 per 100,000 [26], and 62.7% of
HCC cases are attributable to chronic hepatitis B virus
infection [27]. In Korea, liver cancer is the second-most
common cause of death from cancer and was estimated
to be responsible for approximately 11,560 deaths in
2014 and ranked first in terms of the total economic
burden during 2001–2010 [28, 29].
Eligibility criteria
Eligible participants are adults aged 20–70 without his-
tory of liver cancer who are at risk of developing primary
hepatic carcinoma (hepatitis B surface antigen positive
[HBsAg+] or anti-hepatitis C virus positive [anti-HCV+]
with cirrhosis, or cirrhosis from any causes), who have
preserved liver function (Child-Pugh class A), and for
whom the absence of a liver tumor has been confirmed
clinically (no symptoms and no elevated tumor marker)
and radiologically (on US, CT, or MRI) at the time of
screening. Exclusion criteria are diagnosis of malignancy
in the last 5 years, possible pregnancy, and severe
cardiovascular, respiratory, renal, or infectious disease.
The presence of cirrhosis will be determined based on
the histologic or radiologic findings, including liver
surface nodularity, margin blunting, segmental hyper-
trophy/atrophy, and findings secondary to portal hyper-
tension (i.e., splenomegaly, esophageal or gastric varices,
ascites, or reverse portal vein flow).
Participant flow
A trained research nurse will introduce the trial to
potentially eligible patients, who will be provided with
detailed information about the trial. They will then be
able to have an informed discussion with participating
physicians, who will obtain written consent if the
patients agree to participate in the trial. Enrolled
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participants will be randomly assigned to either abdominal
US or noncontrast MRI in addition to serum AFP testing
for HCC surveillance (Fig. 1). They will be evaluated by at
least 10 rounds of surveillance tests at 6-month intervals
(with a variation of ±1 month allowed). The first surveil-
lance test will be performed 6 months after the most
recent imaging study showing no evidence of hepatic
malignancy. If a new lesion detected during US or MRI
surveillance is suspected to be malignant according to the
predefined criteria (see Imaging evaluation section) or if
the serum AFP level is elevated in an increasing trend for
two consecutive tests, dynamic contrast-enhanced CT will
be performed [6, 30]. The reference value for AFP is less
than 9 ng/mL at our institution. Additional dynamic liver
MRI may be performed at the discretion of clinicians. If
the surveillance test result is determined to be a false posi-
tive by subsequent tests, the patient will return for the
next scheduled surveillance test. If a patient is confirmed
as having a hepatic malignancy, the patient will receive
standard treatment according to the guidelines [5–8]. We
will continue follow-up of treated patients for at least
5 years to obtain and compare the overall survival rates.
Unscheduled examinations may be performed under
various circumstances. For example, a participant may
visit the hospital and undergo dynamic contrast-enhanced
CT between surveillance tests because of symptoms
such as abdominal pain or hematemesis. We will
record and report all such cases of unscheduled visits
and examinations.
A patient will be considered a dropout, if that partici-
pant 1) withdraws consent, 2) receives liver transplant-
ation without diagnosis of liver cancer, 3) is diagnosed as
having malignancies other than liver cancer, or 4) does
not take two or more consecutive surveillance tests dur-
ing the trial. To minimize dropout, we will periodically
contact participants to remind them of their next sched-
uled surveillance and to encourage participation. We will
also make efforts to obtain relevant information from
patients lost to follow-up; for example, if a patient is
transferred to a different hospital after hepatic malig-
nancy is diagnosed through this trial, we will contact the
patient and ask for information on the results of
follow-up treatment or pathological diagnosis.
Ultrasonography
Abdominal noncontrast US will be performed using
commercially available machines (Pro-Sound Alpha10 or
Pro-Sound F75, Hitachi Aloka Medical, Tokyo, Japan;
ACUSON S2000, Siemens Medical Solutions, Mountain
View, CA, USA; iU22, Philips Medical Systems, Best,
The Netherlands) with 5-MHz curved-array transducers.
Instead of designating specific investigators to perform
surveillance US for this trial, we will perform surveil-
lance US as in our current clinical practice. At our insti-
tution, surveillance US is performed by well-trained
hepatology fellows. They are trained before they start
practicing abdominal US, and during the first month of
practice, they perform US under the guidance and super-
vision of faculty members. In performing US, operators
follow the guidelines of the Korean Society of
Ultrasound in Medicine [31].
MRI
MRI will be performed using four 3.0-T systems (MAG-
NETOM Trio Tim, Siemens Healthcare, Erlangen,
Germany; Prisma Fit, Siemens Healthcare; Discovery
MR 750, GE Healthcare, Milwaukee, WI, USA; Ingenia
CX, Philips Healthcare, Best, the Netherlands). All im-
ages will be obtained in the transverse plane with a field
of view of 44 cm × 33 cm or 40 cm × 30 cm, according
to the patient’s body size. After obtaining the localizer
images (scanning time: ~ 20 s), T1-weighted images will
be obtained by dual-echo T1-weighted gradient-recalled
echo (GRE) (~ 20 s) and three-dimensional volume
interpolated GRE (~ 20 s) sequences. T2-weighted
images will be acquired by single-shot fat-suppressed
navigator-triggered fast or turbo spin echo sequence
(3–4 min, depending on the regularity of respiration
and patient compliance) and by single-shot breathhold
fast or turbo spin echo sequence with a long echo
time of 140–150 msec (scanning time: ~ 20 s). We
Fig. 1 Participant flow
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will also obtain free breathing or respiratory gated
diffusion-weighted images with b-values of 50, 400,
and 800 s/mm2 (2–4 min), respectively. The apparent
diffusion coefficient will be automatically calculated
and displayed as a corresponding map. The total
scanning time will be approximately 7–10 min,
depending on the MRI machine, and the regularity of
patients’ respiration and their compliance. Details
regarding MRI parameters are presented in Table 1.
Imaging evaluation
Surveillance US findings will be interpreted and re-
ported by the well-trained hepatology fellows. During
US, a suspicious nodule on US is defined as a newly
appearing nodule > 1 cm. Diffuse infiltrative lesions
with or without suspected tumor in the vein are also
considered suspicious for HCC. Simple cysts or le-
sions that have been previously diagnosed as benign
lesions, such as hemangiomas, and show no signifi-
cant interval change are not considered suspicious, ir-
respective of the size.
Surveillance noncontrast MRI will be evaluated by one
of three board-certified abdominal radiologists (MJK,
JYC, and CA). At noncontrast MRI, a suspicious nodule
is defined as a newly appearing nodule > 1 cm that
shows at least one of the following imaging features: T1
hypointensity, T2 hyperintensity, diffusion restriction,
nodule-in-nodule pattern (mosaic appearance), iron
sparing, heterogeneous fatty changes, blood products, or
definite tumor diameter increase. Diffuse infiltrative
lesions with or without a suspected tumor in the vein
are also considered suspicious. Simple cysts, hemangi-
omas, and lesions that have been previously diagnosed
as benign lesions are not considered suspicious, irre-
spective of the size.
Diagnostic dynamic contrast-enhanced CT or MRI will
be evaluated and reported using the Liver Imaging
Reporting and Data System (LI-RADS) [30], by one of
the three board-certified abdominal radiologists (MJK,
JYC, and CA). LI-RADS version 2014 was used at our
institution until June 2017; after that date, we have been
using LI-RADS version 2017.
Reference standards
The final diagnosis will preferably be determined based
on histopathologic findings through surgery (when
appropriate, according to the practice guidelines) or
biopsy. When histopathologic diagnosis is not possible
(i.e., if a patient refuses or cannot tolerate an invasive
procedure) or when invasive biopsy is deemed to do
Table 1 Parameters of surveillance noncontrast MRI
Sequence Scannera Matrix Size ST (mm) Gap (mm) TR (msec) TE (msec) FA (°)
Dual-echo T1-WI GRE Magnetom (2D) 256 × 192 6 1.2 150 1.23/2.46 65
Ingenia (3D) 278 × 256 2 0 3.2 1.15/2.30 10
Discovery (3D) 320 × 256 2 0 3.9 1.12/2.35 12
Prisma (3D) 320 × 256 2 0 9 1.34/2.73 9
T1-WI 3D GRE Magnetom 256 × 192 2 0 2.54 0.95 13
Ingenia 256 × 282 2 0 3.1 1.42 10
Discovery 320 × 288 2 0 4.2 1.9 12
Prisma 320 × 256 2 0 2.68 1.08 9
T2-WI with fat saturation Magnetom 256 × 192 4 1 466 96 150
Ingenia 320 × 212 4 1 758 80 90
Discovery 320 × 256 4 1 2800 80 90
Prisma 320 × 182 4 1 620 105 107
T2-WI with long TE Magnetom 320 × 168 4 1 450 148 150
Ingenia 320 × 186 4 1 522 150 90
Discovery 320 × 224 4 1 840 150 90
Prisma 320 × 208 4 1 600 153 98
DWI Magnetom 128 × 96 6 1 5200 67 90
Ingenia 128 × 128 5 1 4848 55 90
Discovery 128 × 80 5 1 4800 51 90
Prisma 140 × 112 5 1 5500 63 90
aFull scanner names are Magnetom Trio Tim (Siemens), Ingenia CX (Philips), and Discovery MR750 (GE), and Prisma Fit (Siemens)
2D Two-dimensional, 3D Three-dimensional, ST Slice thickness, TR Repetition time, TE Echo time, FA Flip angle, GRE Gradient-recalled echo,
DWI Diffusion-weighted imaging
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more harm than good (i.e., a patient with radiologically
definite HCC at an advanced stage in whom curative
treatment is not indicated), radiologic diagnosis will be
applied. For radiologic diagnosis, lesions categorized as
LR-5, LR-5 V (LR-TIV in LI-RADS version 2017), or
LR-M according to the LI-RADS diagnostic algorithm
will be diagnosed as hepatic malignancies [30].
Outcomes
The primary endpoints are detection rates of very early
or early stage HCC, stage distribution at the initial diag-
nosis, and false positive referral rates. The detection rate
is defined as the number of patients whose liver cancer
is detected using a given surveillance modality divided
by the total number of patients under surveillance with
the modality, expressed as a percentage. Very early stage
cancer is defined as a single tumor < 2 cm, and early
stage cancer is defined as a single tumor < 5 cm or up to
three tumors < 3 cm [7, 8]. Surveillance is considered a
failure when patients are diagnosed at late (i.e., inter-
mediate or advanced) stages. The false positive rate is
defined as the number of positive tests that are eventu-
ally confirmed as negative on subsequent dynamic im-
aging and/or pathologic examination divided by the total
number of tests in a specific surveillance modality,
expressed as a percentage. The secondary endpoints are
5- and 10-year overall survival rates. We will report
these long-term outcomes in separate papers.
Sample size
Based on the past prevalence of HCC in at-risk patients
undergoing surveillance in our institution, we anticipate
that the prevalence of HCC in our study cohort will be
approximately 18% over a study period of 5 years. The
diagnostic sensitivities of noncontrast US and noncon-
trast MRI are expected to be 60% and 90%, respectively
[10, 25]. Based on these expected prevalence and sensi-
tivities, and an anticipated dropout rate of 15%, we cal-
culated that we would need a sample size of 416 patients
(208 for each group) to yield 80% power (1 minus the
probability of a type II error) to detect a significant
difference in detection rate between the noncontrast US
and noncontrast MRI arms, with a two-sided type I error
of 5% [32].
Randomization and blinding
A research nurse will assign participants into either the
noncontrast US group or the noncontrast MRI
surveillance group according to a computer-generated
randomization list. The randomization sequence will be
created using SAS 9.2 (SAS Institute, Inc., Cary, NC,
USA) statistical software by an investigator with no clin-
ical involvement in the trial, with a 1:1 allocation using a
random block size of 4. Only the research nurse will
have knowledge of the randomization sequence. How-
ever, once investigators obtain a participant’s consent
and the research nurse assigns him or her to the non-
contrast US or noncontrast MRI group, the participant
and investigators will inevitably be aware of the surveil-
lance assignment at the time of the initial surveillance
examination. Therefore, blinding of participants and
investigators is not possible for this trial.
Data management
We will use the Electronic Case Reporting System with
Accuracy, Safety, and Efficacy (e-CASE)—a web-based
case report form (https://ecase.yuhs.ac)—for data man-
agement. The research nurse will enter data into the
e-CASE, and a trained data manager will periodically
check the accuracy and completeness of the entered
data. The data will be kept in the archive of the data
center, which has built-in security features preventing
unauthorized access. Only investigators, a research
nurse, and an independent monitor who will perform
data monitoring and auditing will have access to the full
dataset. Personal information about participants will be
coded and depersonalized.
Statistical analysis
Both intention-to-treat (considering all patients as ran-
domized irrespective of the surveillance test they actually
receive) and per-protocol analyses will be performed.
The detection rate, stage distribution, and false positive
rates will be compared between the noncontrast US and
noncontrast MRI arms using the Fisher’s exact or
chi-square test. To compare the variables between the
two groups, we will use the independent t-test or
Mann-Whitney U test for continuous variables and the
chi-square or Fisher exact test for categorical variables.
If necessary, we will perform logistic regression analysis
to determine the independent associations between vari-
ables. Survival will be compared using the Kaplan-Meier
methods with log-rank test. Cox proportional hazard re-
gression will be performed to determine the independent
associations between survival and potential explanatory
variables.
Subgroup analyses will be performed. We will perform
the analyses after excluding patients in whom liver
cancer is diagnosed at their first MRI surveillance tests
following the negative US prior to study enrollment. We
will compare the tumor stages between patients diag-
nosed at the first tests and those diagnosed at later tests
among patients undergoing noncontrast MRI surveil-
lance. These analyses are intended to examine and
exclude the possibility that the tumors already exist but
are missed by the noncontrast US test prior to enroll-
ment. In addition, we will examine the effects of the
quality of the echogenic window to the liver and the
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parenchymal nodularity on our primary endpoints. Fur-
thermore, we will explore the additional benefit of serum
AFP testing in conjunction with noncontrast US or
noncontrast MRI for the detection of early stage HCC.
Two-sided p-values < 0.05 are considered statistically
significant. All statistical analyses will be performed
using the SAS 9.2 software package.
Monitoring
Interventions used for this trial are US and MRI, which
are the widely used imaging tests whose adverse events
are reported very rarely [33]. Furthermore, in this trial,
these imaging tests will be performed without the use of
contrast media. Therefore, there is no harm particularly
anticipated from this study other than the inherent min-
imal risks of the imaging tests themselves. Nevertheless,
we will monitor and record any adverse events occurring
after study enrolment at every visit. Any serious adverse
event will be reported to our IRB. As this study pose a
minimal risk to participants as stated above, we will
nominate a physician independent of this study as an in-
dependent safety monitor (ISM), but there will not be a
formal data and safety monitoring committee. The ISM
will review annually the trial processes and accumulating
data, and determine if the trial should be modified or
discontinued.
Discussion
Our goal is to determine whether surveillance with non-
contrast MRI can further improve the overall survival of
patients at high risk of developing HCC, compared with
surveillance using noncontrast US. To achieve this goal,
we have designed this study as a two-arm randomized
trial. However, no previous study has investigated the
performance of noncontrast MRI in detecting HCC pa-
tients at early stages in a surveillance setting, although
one study examined the diagnostic performance of non-
contrast MRI to detect and diagnose HCC in a limited
cohort of patients, primarily at very early or early stages
[25]. Thus, we first set our primary endpoints as detec-
tion rate of early-stage HCC and false positive rate. At
long-term follow-up of the current study cohort, we may
observe a significant difference in overall survival be-
tween the two arms; if this is not possible, an appropri-
ate sample size could be calculated based on the results
of current trial for a future large-scale, multicenter trial.
We will perform surveillance every 6 months using
both serum AFP and imaging tests, since the combined
use of noncontrast US and AFP is recommended for
surveillance in many practice guidelines published in
Asia, including Korea [5, 6]. Inclusion of AFP may be a
confounding factor in comparing the two imaging
modalities. However, it would be unethical to exclude
serum AFP testing from HCC surveillance for the sake
of a clinical trial because the current evidence points to
noncontrast US combined with serum AFP as the most
effective surveillance strategy [34]. One advantage of this
study design, however, is that this trial will allow us to
assess the benefit of AFP performed in addition to US or
MRI in HCC surveillance, by examining the proportion
of cases where early-stage HCC is detected by AFP
elevation with negative US or MRI results.
We will not designate experienced radiologists specif-
ically for our surveillance US. Instead, as is currently
practiced at our institution, well-trained hepatology fel-
lows will perform surveillance US. In real-world clinical
settings, many patients receive their surveillance US ex-
aminations in local community clinics instead of tertiary
care centers, often by less-experienced US operators
with less-than-optimal protocols or equipment [35]. It
would be unrealistic to have all surveillance US exami-
nations performed exclusively by a limited number of
highly experienced operators.
MIRACLE-HCC is the first clinical trial to compare
the effectiveness of noncontrast MRI and noncontrast
US in the surveillance of HCC in at-risk patients. The
results of this trial will show whether noncontrast MRI
surveillance is superior to noncontrast US surveillance
in the early detection of HCC, whether it results in fewer
false referrals, and whether it can eventually improve the
overall survival of HCC patients.
Additional file
Additional file 1: Explanation for study participants (Translated version).
This document describes the purposes, procedures, benefits, risks,
inconveniences, and precautions of this study. All the patients read this
document and fully understood the explanation of the study, before they
decided whether or not they would agree to participate in the study.
This document is a translated version from the original one written in
Korean. (DOCX 22 kb)
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